Novartis Aktie

129,80 EUR -0,35 EUR -0,27 %

19:01:47

STU

130,14 EUR -0,46 EUR -0,35 %

18:59:45

HAML

Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.239,16 Mrd. EUR

KGV18,30Div. Rendite3,38%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

10.10.25PR NewswireCIBC to transfer 11 European Canadian Depositary Receipt listings to TSX

30.09.25PR NewswireNovartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

03.09.25PR NewswireArgo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

WerbungNovartis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

11.08.25PR NewswireNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

31.07.25PR NewswireNovartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

03.07.25PR NewswireNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

20.06.25PR NewswireNYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth

12.06.25GlobeNewswireNovartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

02.06.25GlobeNewswireNovartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

01.06.25GlobeNewswireNovartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

27.05.25GlobeNewswireNovartis announces commencement of tender offer to acquire Regulus Therapeutics

15.05.25GlobeNewswireNew Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

30.04.25GlobeNewswireNovartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

29.04.25GlobeNewswireNovartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

29.04.25GlobeNewswireNovartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal

03.04.25PR NewswireNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

03.04.25GlobeNewswireNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

31.03.25GlobeNewswireNovartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

28.03.25GlobeNewswireFDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

25.03.25GlobeNewswireNovartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

21.03.25PR NewswireNovartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

21.03.25GlobeNewswireNovartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

19.03.25GlobeNewswireNew Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

07.03.25GlobeNewswireNovartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

07.03.25GlobeNewswireAktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut

28.02.25PR NewswireNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28.02.25GlobeNewswireNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28.02.25GlobeNewswireNovartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

20.02.25PR NewswireBMO Expands Canadian Depositary Receipt (CDR) Lineup with 10 New Listings from Europe and Japan

19.02.25PR NewswireCIBC introduces additional European Canadian Depositary Receipts ("CDRs")

11.02.25GlobeNewswireNovartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

31.01.25GlobeNewswireNovartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

31.01.25GlobeNewswireNovartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen

13.01.25GlobeNewswireNovartis Entresto® US patent upheld by US Court of Appeals

30.12.24GlobeNewswireNovartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.